|
US5595756A
(en)
|
1993-12-22 |
1997-01-21 |
Inex Pharmaceuticals Corporation |
Liposomal compositions for enhanced retention of bioactive agents
|
|
US6455677B1
(en)
|
1998-04-30 |
2002-09-24 |
Boehringer Ingelheim International Gmbh |
FAPα-specific antibody with improved producibility
|
|
US6465181B2
(en)
|
1999-03-25 |
2002-10-15 |
Abbott Laboratories |
Reagents and methods useful for detecting diseases of the prostate
|
|
ES2275513T3
(es)
|
1999-05-17 |
2007-06-16 |
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Und Zum Vertrieb Von Pharmaka Mbh |
Propiedades neuroprotectoras de gdf-15, un miembro de la superfamilia de tgf-beta.
|
|
WO2002020759A2
(en)
|
2000-09-08 |
2002-03-14 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
|
|
AU2005205533B2
(en)
|
2004-01-07 |
2012-03-22 |
Novartis Vaccines And Diagnostics, Inc. |
M-CSF-specific monoclonal antibody and uses thereof
|
|
US8192735B2
(en)
|
2004-04-13 |
2012-06-05 |
St Vincent's Hospital Sydney Limited |
Method for modulating appetite
|
|
WO2007067500A2
(en)
|
2005-12-05 |
2007-06-14 |
Genomic Health, Inc. |
Predictors of patient response to treatment with egfr inhibitors
|
|
CN101854947A
(zh)
|
2007-08-16 |
2010-10-06 |
圣文森特医院悉尼有限公司 |
用于调节巨噬细胞抑制因子(mic-1)活性的药剂和方法
|
|
WO2009046495A1
(en)
|
2007-10-09 |
2009-04-16 |
St Vincent's Hospital Sydney Limited |
A method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
|
|
WO2009150255A2
(en)
|
2008-06-13 |
2009-12-17 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Markers for predicting response and survival in anti-egfr treated patients
|
|
BRPI0919531A2
(pt)
|
2008-09-29 |
2015-12-08 |
Roche Glycart Ag |
anticorpos contra il17 humana e usos dos mesmos
|
|
JP5836125B2
(ja)
|
2008-10-16 |
2015-12-24 |
ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション |
高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
|
|
EP2209003A1
(en)
|
2009-01-16 |
2010-07-21 |
F. Hoffmann-Roche AG |
Means and methods for differentiating between fibrosis and cirrhosis
|
|
US7736861B1
(en)
|
2009-10-19 |
2010-06-15 |
Aveo Pharmaceuticals, Inc. |
Tivozanib response prediction
|
|
US20120309697A1
(en)
|
2009-10-28 |
2012-12-06 |
Samuel Norbert Breit |
Methods of diagnosing and prognosing colonic polyps
|
|
US9212221B2
(en)
|
2010-03-03 |
2015-12-15 |
Detroit R & D, Inc. |
Form-specific antibodies for NAG-1 (MIC-1, GDF-15), H6D and other TGF-β subfamily and heart disease and cancer diagnoses
|
|
WO2011127219A1
(en)
|
2010-04-06 |
2011-10-13 |
Caris Life Sciences Luxembourg Holdings |
Circulating biomarkers for disease
|
|
EP2388594A1
(en)
|
2010-05-17 |
2011-11-23 |
Roche Diagnostics GmbH |
GDF-15 based means and methods for survival and recovery prediction in acute inflammation
|
|
MX355060B
(es)
|
2010-11-17 |
2018-04-03 |
Chugai Pharmaceutical Co Ltd |
Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
|
|
EP2506015A1
(en)
|
2011-04-01 |
2012-10-03 |
Universität Regensburg |
A prognostic and therapeutic signature for malignant melanoma
|
|
ES2704038T3
(es)
|
2011-05-24 |
2019-03-13 |
Zyngenia Inc |
Complejos multiespecíficos multivalentes y monovalentes y sus usos
|
|
WO2013012648A1
(en)
|
2011-07-15 |
2013-01-24 |
Emory University |
Gdf15 in diagnostic and therapeutic applications
|
|
US8790651B2
(en)
|
2011-07-21 |
2014-07-29 |
Zoetis Llc |
Interleukin-31 monoclonal antibody
|
|
CN102321173B
(zh)
|
2011-08-12 |
2013-04-03 |
中国医学科学院肿瘤研究所 |
人源化巨噬细胞抑制因子1单克隆抗体及其应用
|
|
EP2565262A1
(en)
|
2011-08-31 |
2013-03-06 |
VTU Holding GmbH |
Protein expression
|
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
|
AU2013322628B2
(en)
|
2012-09-26 |
2017-03-02 |
Julius-Maximilians-Universitat Wurzburg |
Monoclonal antibodies to growth and differentiation factor 15 (GDF-15)
|
|
CN105073133B
(zh)
|
2012-12-21 |
2021-04-20 |
Aveo制药公司 |
抗gdf15抗体
|
|
CA2906523A1
(en)
|
2013-03-15 |
2014-09-25 |
Myriad Genetics, Inc. |
Genes and gene signatures for diagnosis and treatment of melanoma
|
|
AU2015206603B9
(en)
|
2014-01-14 |
2019-07-18 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
|
|
EP2899544B1
(en)
|
2014-01-28 |
2018-12-26 |
Roche Diagnostics GmbH |
Biomarkers for risk assessment and treatment monitoring in heart failure patients who receive B-type natriuretic peptide guided therapy
|
|
SI3134123T1
(sl)
|
2014-02-21 |
2021-08-31 |
Nektar Therapeutics (India) Pvt. Ltd. |
IL-2Rbeta-selektivni agonisti v kombinaciji s protitelesom proti- CTLA-4 ali protitelesom proti-PD-1
|
|
DK3122775T3
(da)
|
2014-03-26 |
2020-02-03 |
Univ Wuerzburg J Maximilians |
Monoklonale antistoffer til vækst- og differentieringsfaktor 15 (gdf-15), og anvendelser deraf til behandling af cancer kakeksi og cancer
|
|
EP3851122A1
(en)
*
|
2014-09-25 |
2021-07-21 |
Aveo Pharmaceuticals Inc. |
Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
|
|
EP3073268A1
(en)
|
2015-03-27 |
2016-09-28 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Biomarker panel for diagnosing cancer
|
|
GB201517528D0
(en)
|
2015-10-02 |
2015-11-18 |
Julius Maximillians Universitãt Würzburg |
GDF-15 as a diagnosis marker for melanoma
|
|
PT3355919T
(pt)
|
2015-10-02 |
2023-01-06 |
Univ Wuerzburg J Maximilians |
Terapia de combinação utilizando inibidores do fator de crescimento e diferenciação 15 (gdf-15) humano e bloqueadores de pontos de controlo imunitários
|
|
DK3356827T3
(da)
|
2015-10-02 |
2024-01-08 |
Univ Wuerzburg J Maximilians |
Gdf-15 som en diagnostisk markør til forudsigelse af det kliniske resultat af en behandling med immun-checkpoint-blokkere
|
|
PT3377534T
(pt)
|
2015-11-18 |
2025-07-10 |
Bristol Myers Squibb Co |
Tratamento do cancro do pulmão utilizando uma combinação de um anticorpo anti-pd-1 e de um anticorpo anti-ctla-4
|
|
US11312766B2
(en)
*
|
2016-04-27 |
2022-04-26 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
|
EP3841121A2
(en)
|
2018-08-20 |
2021-06-30 |
Pfizer Inc. |
Anti-gdf15 antibodies, compositions and methods of use
|
|
US20230212274A1
(en)
|
2020-02-21 |
2023-07-06 |
The Children's Medical Center Corporation |
Method for treating asthma or allergic disease
|
|
CN111393526B
(zh)
|
2020-03-30 |
2022-04-12 |
中国人民解放军第四军医大学 |
抗gdf15中和性单克隆抗体及其应用
|
|
KR20230107309A
(ko)
|
2020-11-10 |
2023-07-14 |
카탈임 게엠베하 |
항-gdf15 항체 및 암 치료용 투여 용법
|